⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

November 12, 2025Infectious Diseases and TherapyOpen Access

High-Dose Minocycline Improves Outcomes in Acinetobacter baumannii Group Pneumonia: A Propensity-Weighted Cohort Study with MIC-Based Insights for Breakpoint Revision

Yu-Tao Tseng Yang Chuan Chen Yi‐Tzu Lee Po Hsiang Liao Dung Hung Chiang Po‐Liang Chen Tzu-Wen Huang Yung Chih Wang

View Full Paper

Ask AI

Bookmark

Share

Abstract

High-dose minocycline significantly improved in-hospital survival for A. baumannii group pneumonia. PK/PD-informed breakpoint may offer greater clinical relevance for guiding minocycline therapy compared to CLSI 2024 breakpoint.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tseng et al. (2025) studied this question.

synapsesocial.com/papers/692523d9c0ce034ddc355909 https://doi.org/10.1007/s40121-025-01260-w

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Minocycline-based therapy for carbapenem-resistant Acinetobacter baumannii pneumonia: A multicenter retrospective studyRetrospective Study · 2025 · 4 citations
2Assessment of the revision of the 2025 CLSI breakpoints for the interpretation of minocycline susceptibility for <i>Acinetobacter baumannii</i> complexOriginal Research · 2026 · 2 citations
3An Ancient Drug for a Modern Era: Minocycline for the Treatment of Multi-Drug-Resistant Acinetobacter baumannii2024 · 3 citations
4P-1348. Impact of Minocycline Minimum Inhibitory Concentrations on Clinical Outcomes in Stenotrophomonas maltophilia Respiratory and Bloodstream InfectionsCohort Study · 2026
5The pharmacodynamics of polymyxin B in <i>Acinetobacter baumannii</i> in murine thigh and lung infection modelsOriginal Research · 2026